Compared to the WHO Global Hepatitis report on viral hepatitis, the number of deaths due to HCC had been increasing in Japan since 1975. This number of deaths started to increase consistently until it reached its peak of 34 637 per year in 2002, but it decreased gradually until it reached <30 000 per year in 2014. 4 Although mortality has been decreasing annually, HCC still ranks as the fourth common cause of death due to malignancy in men and the sixth common cause of death in women in Japan. 5 By its aetiology, HBV contributes 53%
and HCV 25% to liver cancer worldwide. But, this is inverted in Japan,
where it is estimated that the contribution of HCV is 66%. 6 Since 2000, the Japanese government has pursued an aetiologybased hepatitis and HCC control health policy and strategy based on large-scale epidemiologic or clinico-pathological studies. 7 In accordance with the national health policy, the hepatitis epidemiological research groups of The Ministry of Health, Labor, and Welfare (MHLW) in Japan estimate the number of undiagnosed hepatitis virus carriers and patients with hepatitis virus-related disease with respect to sex-specific and age-specific groups using the data collected by the Japanese Red Cross Blood Center in the same year. 8, 9 MHLW declared that the estimated number of hepatitis virus carriers and patients with hepatitis virus-related disease was about 3.0-3.7 million persons in 2000. This declaration was based on an estimation of undiagnosed carriers aged between approximately 15 and 69 years in 2000. 8 Based on this estimation, the countermeasures for viral hepatitis infection control and prevention were started and focused on screening.
As a part of the countermeasure system, it is important to estimate the numbers of hepatitis virus carriers and patients in 2011, using results from large-scale epidemiological studies and national reports to determine the actual trends in the numbers of carriers from 2000 to 2011.
The aim of this study was to determine the trend of total numbers of HBV and HCV carriers over the last 11 years by each liver disease state (AC, CH, LC and HCC) and different states of HBV and HCV carriers linked to the society (undiagnosed carrier, diagnosed carriers who are consulting at the hospital, diagnosed carriers who are not consulting at the hospital, newly infected carrier, cured person and death from 2000 to 2011), and according to this figure we can evaluate the effectiveness of the countermeasure against hepatitis and we can also adopt new strategies based on the outcome of current interventions.
| MATERIALS AND METHODS
In this study, we estimated the number of hepatitis virus carriers and patients with hepatitis virus-related disease with respect to sexspecific and age-specific groups in Japan.
| Classification of 6 groups of hepatitis virus carriers in Japan
A carrier state can be further subdivided into 6 groups as follows. 
| Estimates for the number of undiagnosed carriers
The number of undiagnosed HBV and HCV carriers who were unaware of their infection in 2000 and 2011 was estimated by calculating the sum of products of sex-specific, age-specific and area-specific for 65-69 years). Symbols r ijk and P ijk denote the carrier rate and total population among the group of area i, sex j, and age k. We assumed that the carrier rate among people aged 70 and older would be the same as that for those aged 60-69 years. (Figure 1 ).
We also assumed all people whose hepatitis B surface antigen became positive were HBV carriers. At the same time, 70% of those with anti-HCV positivity were assumed to be HCV carriers. The number of undiagnosed carriers based on a clinical diagnosis (asymptomatic carrier, chronic hepatitis, LC and HCC) was estimated as a proportion with respect to the per cent distribution of each clinical diagnosis.
| Distribution pattern of the clinical diagnosis of undiagnosed HCV carriers in 2000
The distribution pattern of clinical diagnosis of 906 HCV carriers among blood donors in Hiroshima 11, 12 (Appendix 1) was used as a baseline.
| Distribution pattern of the clinical diagnosis of undiagnosed HCV carriers in 2011
The (Appendix 1). Additionally, the transition probabilities were determined among 938 HBV carriers who were followed up at Narao Hospital. Proportions of HBV and HCV carriers among each liver disease were assumed to be 13:65 for LC 16 and 17:72 for malignant neoplasm of the liver and intrahepatic bile ducts. 17 We assumed a proportion of 13:65 for chronic hepatitis, which was the same as LC. In this study, viral hepatitis B and C were assumed as chronic hepatitis B and C, respectively. 
| Patients with HBV-and HCV-related disease aged ≤64 years in 2011
Patients aged <64 years were included in the estimation of the number of hepatitis virus-related diseases using medical receipts for insurance claims as follows. 10 We collected the medical claims related to hepatitis virus-related diseases from a database of 582 922-787 075 employees and their family members and summarized the diagnosis individually. Then, we estimated the sex-specific and age-specific 1-year prevalence of each hepatitis virus-related disease. Finally, we estimated the number of patients by the sum of the products of the sex-specific and age-specific 1-year prevalence and total population in Japan.
| Patients with HBV-and HCV-related disease aged ≥65 years and older in 2011
The number of patients aged ≥65 years was included in the patient survey in 2011. 15 The number of patients aged ≥65 years with a malignant neoplasm of the liver and intrahepatic bile ducts, chronic hepatitis and LC was calculated based on each age-specific group.
Proportions of HBV and HCV among each liver disease were assumed to be 14:71 for LC and chronic hepatitis 19 and 17:72 for a malignant neoplasm of the liver and intrahepatic bile ducts. 17 We assumed that chronic viral hepatitis B (ICD code: B18.0-18.1) and C (ICD code: B18.2) were chronic hepatitis B and C, respectively. The proportion of patients aged ≥65 years among all patients with viral hepatitis B and C was the same as that for those with chronic hepatitis.
| Estimates for the number of unconsulted or ceased carriers in 2011
This was estimated by subtracting the numbers of the 4 groups (undiagnosed carriers, patients, cured carriers and deaths) in 2011 from the total of number of carriers (undiagnosed carriers and patients) in 2000.
| Estimates for the number of new infections from 2000 to 2011
These incidences were estimated by summing the product of sexspecific and age-specific incidence rates among 219 292 and 218 797 blood donors during 1994-2004 in Hiroshima with respect to the total population 20 :
where j, k denote the index of sex and age groups. Symbols ir jk and P jk denote the incidence rate and total population among the groups of sex j and age k, respectively.
| Estimates for the number cured from 2000 to 2011
We assumed that no one with HBV infection was completely cured. For HCV, this statistical report was used for the number of interferon (IFN) treatments: "Issued record of application for government-subsidized medical expense of hepatitis IFN were assumed as 70% and 30%, respectively). CR rates for patients with genotype 1b and genotype 2 were 50% and 80%, respectively. 
| Estimates for the number of deaths from 2000 to 2011
Numbers of deaths from 2000 to 2011 were estimated using the all- In this estimation, we assumed the following: the age range for all patients is more than 40 years, and the risk ratio of persistent infection of HBV or HCV is 1.
| Ethical Consideration
No ethical issues occurred in this study, because only census data and published data were used as the data source.
| RESULTS
The number of hepatitis virus carriers and patients with hepatitis Tables 1 and 2 .
| DISCUSSION
In Japan, various national strategies to trace the number of infected person were introduced only after discovery of the specific virus and techniques to detect the virus in humans as early as the 1980s. After 1986, screening for pregnant women was introduced to prevent has established well-coordinated and collaborated hepatitis treatment systems with regional core centres, specialized institutions for hepatitis treatment and primary care doctors. 7 The alleviation of medical costs, ie the medical expense aid system, was launched in 2008.
Moreover, the "Basic Act on Hepatitis Measures" was established to address hepatitis virus infection, and it was adopted by the whole country in 2009. 7 This act is unique and not found in other countries.
According to the act, various measures to advance the existing screening system, diagnosis and treatment of liver complication were implemented by various action plans such as hepatitis virus screening for all residents irrespective of age, a medical expense aid system and the establishment of core hospitals for hepatitis treatment in all prefectures.
To get a better control on viral hepatitis, it is important to know the index burden of disease in Japan. Therefore, we have already reported the estimated total number of undiagnosed HBV and HCV carriers in Secondly, the number of untreated patients coincidently increased to some extent. It is strongly recommended to improve awareness campaign by using mass media outlets, such as television, websites, pamphlets and radio. In addition, the proper and effective referral 706  0~69  50~59  40~49  30~39  20~29  10~19  0~9   706  0~69  50~59  40~49  30~39  20~29  10~19  0~9   706  0~69  50~59  40~49  30~39  20~29  10~19  0~9   706  0~69  50~59  40~49  30~39  20~29  10~19  0~9   706  0~69  50~59  40~49  30~39  20~29  10~19  0~9   706  0~69  50~59  40~49  30~39  20~29  10~19  0~9   706  0~69  50~59  40~49  30~39  20~29  10~19  0~9   706  0~69  50~59  40~49  30~39  20~29  10~19 system from the screening centre to the treatment centre (core hospitals) should be upgraded. 7 The follow-up observation of positive carriers throughout their life should be continued by regional health care (a private or primary care doctor). Hence, the operation system of regional core hospital should be upgraded and promoted. Most importantly, the natural disease course should be explained to people, and then, proper counselling and health education should be given to positive carriers after screening. The counselling must encompass how important it is to consult with a hepatologist once and undergo further investigation and a follow-up visit at the designated treatment centre or core hospital. These 2 outcomes are the strong evidence to adopt the new national strategy on viral hepatitis and HCC control in Japan.
In fact, the actual figures of morbidity and mortality of hepatitis virus-related disease can vary by prefecture. In some prefectures (eg the Saga prefecture), the mortality due to HCC is so high that the disease becomes a priority among other public health problems. But T A B L E 2 Estimated number of persons with persistent HCV or HBV infection at 2011 the mortality rate may be low in other prefectures. This proves the possible use of the countermeasure system in determining the actual figure of infection, and it helps develop more effective strategic plans based on the prefecture's own needs. Although the strategic plan can vary by prefecture, it must strictly follow the "Basic Act on Hepatitis
Measures." Yearly review and evaluation of the existing system and strategic plans can be performed based on the significant outcomes reported according to these countermeasures, and then, any action plans of public health promotion can be decided.
Although the overall number of viral hepatitis carriers in Japan has decreased to some extent, the frequency of HCC is still high among all cancer-related deaths. Most patients with HCC in Japan have underlying viral hepatitis, in which HCV accounts for two-thirds of the patients while HBV accounts for about 15%. To reduce the disease-specific mortality rate related to hepatitis virus, it is recommended to upgrade the promotion of nationwide screening system including screening at risk person, screening of blood donors, haemodialytic patients, recipient of repeated blood transfusion due to haematological disorders such as thalassaemia, continuous medical education and using of newly discovered effective drugs with standard regime, promoting the referral system and core hospitals.
In addition, prefecture-specific health strategies should be allo- We thank the Japanese Red Cross Society for supports for this study.
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